×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VRTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/23
04:05 pm
vrtx
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Low
Report
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
12/23
03:19 pm
vrtx
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance]
Low
Report
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance]
12/23
10:31 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a "sector perform" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a "sector perform" rating on the stock.
12/23
10:31 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.
12/23
09:08 am
vrtx
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $503.00 to $500.00. They now have an "overweight" rating on the stock.
Low
Report
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $503.00 to $500.00. They now have an "overweight" rating on the stock.
12/23
07:45 am
vrtx
Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
Low
Report
Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
12/20
03:46 pm
vrtx
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Low
Report
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
12/20
03:35 pm
vrtx
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Neutral
Report
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2024
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
5.7%
vertex pharmaceuticals incorporated
8/1/2024
04:01 pm
vrtx
vertex pharmaceuticals incorporated
MISS
Report
-2.2%
vertex pharmaceuticals incorporated
5/6/2024
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
1.9%
vertex pharmaceuticals incorporated
2/5/2024
04:06 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-2.7%
vertex pharmaceuticals incorporated
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/20
03:52 pm
vrtx
Form 8-K VERTEX PHARMACEUTICALS For: Dec 20
Low
Report
Form 8-K VERTEX PHARMACEUTICALS For: Dec 20
11/19
04:09 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Nov 15 Filed by: ALTSHULER DAVID
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Nov 15 Filed by: ALTSHULER DAVID
11/15
10:31 am
vrtx
Form 144 VERTEX PHARMACEUTICALS Filed by: ALTSHULER DAVID
Low
Report
Form 144 VERTEX PHARMACEUTICALS Filed by: ALTSHULER DAVID
11/13
04:15 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Nov 11 Filed by: WAGNER CHARLES F JR
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Nov 11 Filed by: WAGNER CHARLES F JR
11/12
04:09 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Nov 08 Filed by: Kewalramani Reshma
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Nov 08 Filed by: Kewalramani Reshma
11/12
09:44 am
vrtx
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
Low
Report
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
11/8
02:59 pm
vrtx
Form 144 VERTEX PHARMACEUTICALS Filed by: Kewalramani Reshma
Low
Report
Form 144 VERTEX PHARMACEUTICALS Filed by: Kewalramani Reshma
11/5
04:13 pm
vrtx
Form 10-Q VERTEX PHARMACEUTICALS For: Sep 30
Low
Report
Form 10-Q VERTEX PHARMACEUTICALS For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
TOP News Decliners
1/30
Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool]
-6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: